292 related articles for article (PubMed ID: 22613170)
1. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study.
McDonald BC; Conroy SK; Smith DJ; West JD; Saykin AJ
Brain Behav Immun; 2013 Mar; 30 Suppl(0):S117-25. PubMed ID: 22613170
[TBL] [Abstract][Full Text] [Related]
2. Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion.
Nudelman KN; Wang Y; McDonald BC; Conroy SK; Smith DJ; West JD; O'Neill DP; Schneider BP; Saykin AJ
PLoS One; 2014; 9(5):e96713. PubMed ID: 24816641
[TBL] [Abstract][Full Text] [Related]
3. Diminished gray matter density mediates chemotherapy dosage-related cognitive impairment in breast cancer patients.
Li X; Chen H; Lv Y; Chao HH; Gong L; Li CR; Cheng H
Sci Rep; 2018 Sep; 8(1):13801. PubMed ID: 30218006
[TBL] [Abstract][Full Text] [Related]
4. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study.
McDonald BC; Conroy SK; Ahles TA; West JD; Saykin AJ
Breast Cancer Res Treat; 2010 Oct; 123(3):819-28. PubMed ID: 20690040
[TBL] [Abstract][Full Text] [Related]
5. Impairment of the executive function in breast cancer patients receiving chemotherapy treatment: a functional MRI study.
Tao L; Lin H; Yan Y; Xu X; Wang L; Zhang J; Yu Y
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27436790
[TBL] [Abstract][Full Text] [Related]
6. Clinical Significance of Fronto-Temporal Gray Matter Atrophy in Executive Dysfunction in Patients with Chronic Kidney Disease: The VCOHP Study.
Tsuruya K; Yoshida H; Haruyama N; Fujisaki K; Hirakata H; Kitazono T
PLoS One; 2015; 10(12):e0143706. PubMed ID: 26632813
[TBL] [Abstract][Full Text] [Related]
7. Executive Function Alternations of Breast Cancer Patients After Chemotherapy: Evidence From Resting-state Functional MRI.
Wang L; Yan Y; Wang X; Tao L; Chen Q; Bian Y; He X; Liu Y; Ding W; Yu Y; Qiu B
Acad Radiol; 2016 Oct; 23(10):1264-70. PubMed ID: 27346235
[TBL] [Abstract][Full Text] [Related]
8. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?
Ganz PA; Bower JE; Kwan L; Castellon SA; Silverman DH; Geist C; Breen EC; Irwin MR; Cole SW
Brain Behav Immun; 2013 Mar; 30 Suppl(Suppl):S99-108. PubMed ID: 22884417
[TBL] [Abstract][Full Text] [Related]
9. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging.
de Ruiter MB; Reneman L; Boogerd W; Veltman DJ; Caan M; Douaud G; Lavini C; Linn SC; Boven E; van Dam FS; Schagen SB
Hum Brain Mapp; 2012 Dec; 33(12):2971-83. PubMed ID: 22095746
[TBL] [Abstract][Full Text] [Related]
10. Long-term cognitive impairment of breast cancer patients after chemotherapy: A functional MRI study.
Miao H; Li J; Hu S; He X; Partridge SC; Ren J; Bian Y; Yu Y; Qiu B
Eur J Radiol; 2016 Jun; 85(6):1053-7. PubMed ID: 27161051
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal investigation of cognitive deficits in breast cancer patients and their gray matter correlates: impact of education level.
Perrier J; Viard A; Levy C; Morel N; Allouache D; Noal S; Joly F; Eustache F; Giffard B
Brain Imaging Behav; 2020 Feb; 14(1):226-241. PubMed ID: 30406352
[TBL] [Abstract][Full Text] [Related]
12. Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy.
Nudelman KN; McDonald BC; Wang Y; Smith DJ; West JD; O'Neill DP; Zanville NR; Champion VL; Schneider BP; Saykin AJ
J Clin Oncol; 2016 Mar; 34(7):677-83. PubMed ID: 26527786
[TBL] [Abstract][Full Text] [Related]
13. Brain gray matter reduction and premature brain aging after breast cancer chemotherapy: a longitudinal multicenter data pooling analysis.
de Ruiter MB; Deardorff RL; Blommaert J; Chen BT; Dumas JA; Schagen SB; Sunaert S; Wang L; Cimprich B; Peltier S; Dittus K; Newhouse PA; Silverman DH; Schroyen G; Deprez S; Saykin AJ; McDonald BC
Brain Imaging Behav; 2023 Oct; 17(5):507-518. PubMed ID: 37256494
[TBL] [Abstract][Full Text] [Related]
14. [Cognitive function in breast cancer patients on chemotherapy: a longitudinal study].
Chen X; Li J; Zhu C; Li D; Zhang J; Wang K
Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(1):27-30. PubMed ID: 24721302
[TBL] [Abstract][Full Text] [Related]
15. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
[TBL] [Abstract][Full Text] [Related]
16. Evidence of gray matter reduction and dysfunction in chromosome 22q11.2 deletion syndrome.
Shashi V; Kwapil TR; Kaczorowski J; Berry MN; Santos CS; Howard TD; Goradia D; Prasad K; Vaibhav D; Rajarethinam R; Spence E; Keshavan MS
Psychiatry Res; 2010 Jan; 181(1):1-8. PubMed ID: 19962860
[TBL] [Abstract][Full Text] [Related]
17. Brain structure and function in patients with ovarian cancer treated with first-line chemotherapy: a pilot study.
Correa DD; Root JC; Kryza-Lacombe M; Mehta M; Karimi S; Hensley ML; Relkin N
Brain Imaging Behav; 2017 Dec; 11(6):1652-1663. PubMed ID: 27766586
[TBL] [Abstract][Full Text] [Related]
18. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features.
Ossenkoppele R; Pijnenburg YA; Perry DC; Cohn-Sheehy BI; Scheltens NM; Vogel JW; Kramer JH; van der Vlies AE; La Joie R; Rosen HJ; van der Flier WM; Grinberg LT; Rozemuller AJ; Huang EJ; van Berckel BN; Miller BL; Barkhof F; Jagust WJ; Scheltens P; Seeley WW; Rabinovici GD
Brain; 2015 Sep; 138(Pt 9):2732-49. PubMed ID: 26141491
[TBL] [Abstract][Full Text] [Related]
19. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation.
Askren MK; Jung M; Berman MG; Zhang M; Therrien B; Peltier S; Ossher L; Hayes DF; Reuter-Lorenz PA; Cimprich B
Breast Cancer Res Treat; 2014 Sep; 147(2):445-55. PubMed ID: 25138546
[TBL] [Abstract][Full Text] [Related]
20. Microstructural white matter changes and their relation to neuropsychological deficits in patients with juvenile myoclonic epilepsy.
Knake S; Roth C; Belke M; Sonntag J; Kniess T; Krach S; Jansen A; Sommer J; Paulus FM; Carl B; Rosenow F; Hermsen AM; Menzler K
Epilepsy Behav; 2017 Nov; 76():56-62. PubMed ID: 28927715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
